Comparative Pharmacology
Head-to-head clinical analysis: BONCRESA versus FOSAMAX PLUS D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONCRESA versus FOSAMAX PLUS D.
BONCRESA vs FOSAMAX PLUS D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BONCRESA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and readily excreted metabolite, thereby reducing serum uric acid levels.
Alendronate, a bisphosphonate, inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and interfering with the mevalonate pathway, leading to osteoclast apoptosis. Cholecalciferol (vitamin D3) promotes intestinal calcium absorption and bone mineralization.
5 mg orally once daily, with or without food; maximum dose 10 mg once daily.
One tablet (alendronate 70 mg / cholecalciferol 2800 IU) orally once weekly.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14 h); clinically relevant for once-daily dosing
Alendronate: Terminal half-life in bone is estimated at 10+ years due to slow release from the skeleton. Cholecalciferol: Half-life of 25-hydroxyvitamin D is ~15 days.
Renal: 70% unchanged; fecal: 20% as metabolites; biliary: minor (<5%)
Alendronate: ~50% excreted unchanged in urine; remainder is taken up by bone and slowly eliminated. No biliary or fecal excretion of intact drug. Cholecalciferol: ~50% excreted in bile via feces; less than 1% in urine.
Category C
Category C
Bisphosphonate
Bisphosphonate